PRAXIS PRECISION MEDICINES I

Praxis Precision Medicines dips 3% as biotech markets wobble – a 200‑day SMA drop and FDA‑linked trial data could trigger a rebound toward its $392.70 peak.

Praxis Precision Medicines (PRAX) slides 3% after 52‑week peak, trading below its 200‑day average. Explore the upside potential from FDA milestones, partnerships, and its strong neuro‑genetic pipeline.